GI Links

There are many excellent online resources for gastroenterology healthcare professionals and their patients. Remember that it may be best to review more than one site on a topic to gain the best understanding.

Medscape®
www.medscape.com
A medical information site with a gastroenterology area for physicians, nurses, pharmacists, and medical students.
WebMD®
www.webmd.com
Register in the physician section for medical updates, full-text articles on medical practice, services for medical offices, CME and financial news.
Atlas of Gastrointestinal Endoscopy
www.endoatlas.com
Presented by a gastroenterology clinical practice, this site provides access to endoscopic photographs, links and more.
Centers for Disease Control and Prevention
www.cdc.gov
The CDC site has links to news, general and specific disease-oriented health information, publications and software and more.
Crohn's and Colitis Foundation of America
www.ccfa.org
This site is geared towards patients, but has a section for physicians.
Doctor's Guide: Personal Edition: Ulcers and Other Gastric Disorders
www.pslgroup.com/ULCERS.HTM
The physician section has information on ulcers and other GI disorders, conference schedules, medical news and alerts and more.
The Foundation For Clinical Research in Inflammatory Bowel Disease
www.myibd.org
This site is dedicated to providing people with ulcerative colitis and Crohn's disease and their families with accurate information about these inflammatory bowel diseases (IBD) and their treatments.
National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
www.niddk.nih.gov
This site includes research funding opportunities, information on NIDDK laboratories, health information, clinical trials and health education programs.
National Library of Medicine (NLM)
www.nlm.nih.gov
Access health information, NLM publications and libraries, and more.

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.